We are live on ! Find out more
PEARW

Pear Therapeutics, Inc. Warrant
PEARW

Delisted

PEARW was delisted on the 18th of April, 2023.

Back to rankings

44 hedge funds and large institutions have $4.47M invested in Pear Therapeutics, Inc. Warrant in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 51 → 44 (-7)

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

44% less capital invested

Capital invested by funds: $7.97M → $4.47M (-$3.5M)

82% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 11

Holders
44
Holders Change
-7
Holders Change %
-13.73%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
2
Reduced
11
Closed
21
Calls
$2.51M
Puts
–
Net Calls
+$2.51M
Net Calls Change
-$271K

Top Buyers

Rank Fund Capital Flow
1
OCAM
Owl Creek Asset Management
New York
+$420K
2
BlackRock
BlackRock
New York
+$248K
3
AR
Advisory Research
Illinois
+$217K
4
MA
MYDA Advisors
New York
+$60.9K
5
WAM
Wolverine Asset Management
Illinois
+$42.4K

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$1.82M
2
BCM
BlueCrest Capital Management
Jersey
-$317K
3
MF
Magnetar Financial
Illinois
-$262K
4
GCL
Glazer Capital LLC
New York
-$233K
5
Citadel Advisors
Citadel Advisors
Florida
-$200K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$1.08M – – –
LP
2
LMR Partners
United Kingdom
$385K – – –
PSAMP
3
P. Schoenfeld Asset Management (PSAM)
New York
$287K -$97.5K -96,015 -17%
OCAM
4
Owl Creek Asset Management
New York
$248K +$420K +414,000 New
AC
5
Aristeia Capital
Connecticut
$246K – – –
KCM
6
Kingstown Capital Management
New York
$231K – – –
AGC
7
Angelo Gordon & Co
New York
$207K – – –
KC
8
Kepos Capital
New York
$150K – – –
BlackRock
9
BlackRock
New York
$146K +$248K +244,008 New
AR
10
Advisory Research
Illinois
$128K +$217K +213,551 New
SC
11
Sculptor Capital
New York
$123K -$81.2K -79,968 -29%
SRF
12
Silver Rock Financial
California
$113K -$23.3K -22,952 -11%
MCM
13
Moore Capital Management
New York
$100K – – –
AGM
14
Alpine Global Management
New York
$96K -$159K -156,834 -50%
Balyasny Asset Management
15
Balyasny Asset Management
Illinois
$90K -$50.8K -50,000 -25%
DCM
16
Difesa Capital Management
New York
$90K +$152K +150,000 New
AI
17
Arena Investors
New York
$75.7K +$128K +126,122 New
TCA
18
Taconic Capital Advisors
New York
$60K – – –
TI
19
Telemetry Investments
New York
$51K -$40.6K -40,000 -32%
DKCM
20
Davidson Kempner Capital Management
New York
$50K – – –
Citadel Advisors
21
Citadel Advisors
Florida
$48K -$200K -197,086 -71%
CF
22
Cantor Fitzgerald
New York
$48K +$80.9K +79,705 New
PI
23
PEAK6 Investments
Illinois
$40K – – –
WCMNY
24
Westchester Capital Management (New York)
New York
$38K – – –
CCA
25
Castle Creek Arbitrage
Colorado
$37K -$57.6K -56,780 -49%
1
2 3

PEARW Hedge Fund Activity: Q4 2021 in Review

44 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q4 2021, worth a combined $4.47M — down 44% from $7.97M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of PEARW and 14 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 2 added.

The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $420K. The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $1.82M sold.

  • 44 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q4 2021, down from 51 in Q3 2021.
  • Funds reported $4.47M of Pear Therapeutics, Inc. Warrant stock for Q4 2021, down 44% quarter-over-quarter.
  • 14 funds opened new Pear Therapeutics, Inc. Warrant positions in Q4 2021 and 21 closed out, a net change of -7 holders.
  • The largest Pear Therapeutics, Inc. Warrant buyer in Q4 2021 was Owl Creek Asset Management, an estimated $420K added.
  • The largest Pear Therapeutics, Inc. Warrant seller in Q4 2021 was Radcliffe Capital Management, an estimated $1.82M sold.

Based on aggregated 13F filings for Q4 2021.